Overdue Process  

Oleh:

[s.n]

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 22 no. 11 (Nov. 2004), page 1329-1330.
Topik: process; overdue process

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.3 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Health care agencies were blindsided last month by a decision to suspend operations at the UK manufacturing facility of chiron corporation, the world's second largest producer of influenza vaccine. They shouldn't have been, Deviations from good manufacturing standards at the Liverpool plant had been documented two months earlier, and similar problems were detected in June 2003. Even more egg was on faces as a result of chiron's assurance that bacterial contamination would only affect 6 - 8 million doses. It has turned out that none of the company's 2004 batch of vaccine is safe to use, with the result that the US has lost almost half of the 100 million doses it expected to have for this year's flu season. The depleted number of vaccine companies still doing business means that no company is in a position to step in and respond to the shortage.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali